Latest Materials News

Compumedics Limited (ASX:CMP) returned to profit in FY26 as record revenue, stronger cash generation and a sharp rise in MEG and SaaS sales reshaped its earnings profile. The company enters FY27 with A$28.3 million of open orders, but lower gross margins and uneven US and European execution remain key tests.

Charger Metals has reduced its FY2026 loss and secured $3.75 million from the sale of Bynoe, giving the lithium explorer more room to advance its Lake Johnston assets. The company’s Medcalf resource now stands at 10.6Mt, although further drilling and funding will be needed to test its economic potential.

TerraCom has been suspended from trading while it completes audited FY2026 results expected to include material impairments to its South African and Australian assets. The company has not yet disclosed the size or effect of those write-downs.

American Rare Earths has expanded the proposed Cowboy State Mine in Wyoming to a 4.5 million tonne per year operation with a 26-year mine plan and an estimated after-tax NPV of US$1.07 billion. The stronger study case comes with higher capital, lower recoveries and no Ore Reserves, leaving metallurgy, permitting and funding as the next tests.

Macquarie Global Yield Maximiser Fund delivered a 48.6% increase in operating profit and more than doubled net assets to A$340.7 million in the year to 30 June 2026. The expansion came alongside sharply higher distributions, although the portfolio’s larger exposure to debt securities leaves interest rates and credit spreads central to the next phase.

Macquarie Subordinated Debt Fund (ASX:MQS) reported a sharp increase in operating profit and assets for the year ended 30 June 2026, powered by the expansion of its active ETF class. The audited accounts also show the fund’s returns remain closely exposed to interest rates, credit spreads and debt-market valuations.

Walter Scott Global Equity Fund’s operating profit fell to A$4.1 million in 2026 from A$349.5 million, while net assets dropped by about A$1.1 billion. The audited report points to weaker investment gains and substantial redemptions, although the fund remained fully invested in quoted equities and received an unmodified audit opinion.

Pengana International Equities has cancelled 151.1 million shares in a $183.28 million buy-back, leaving a much smaller listed investment company and three fewer directors. The reconstituted board will review capital options before deciding whether to pursue a future rights issue.

Benjamin Hornigold Limited (ASX:BHD) delivered a 9.93% portfolio return in FY2026 but still posted a $420,931 loss after $565,697 in legal fees. Two settlements worth $2.6 million were received after year-end, while an $8.97 million judgment against JB Markets was assigned no value.

Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.

Atlas Arteria has warned that France may more than double the tax rate applied to eligible toll-road operators, with APRR’s 2025 TEILD bill already reaching €126.7 million. The proposed changes remain subject to parliamentary debate and could be softened before becoming law.

Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.